An experimental treatment to repair damage from heart attacks is showing early signs that it may be working in people, the discoverer of the technology said at a major biomedical meeting in La Jolla.
“So far we have complete followup data on two patients, and both did show signs of improved cardiac function,” Karen Christman, scientific founder of San Diego’s Ventrix, said Thursday at the Cell & Gene Meeting on the Mesa.
Christman, a UC San Diego bioengineer, said the ongoing Phase I trial will assess safety and feasibilty in 18 patients who have had heart attacks.
